{"organizations": [], "uuid": "4a8611c38293ca9d08254990141404f5a2a1963d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-athenex-receives-positive-feedback/brief-athenex-receives-positive-feedback-from-fda-on-the-design-of-phase-iii-clinical-trial-for-oraxol-idUSASB0C114", "country": "US", "domain_rank": 408, "title": "BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.51, "site_type": "news", "published": "2018-01-16T21:10:00.000+02:00", "replies_count": 0, "uuid": "4a8611c38293ca9d08254990141404f5a2a1963d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-athenex-receives-positive-feedback/brief-athenex-receives-positive-feedback-from-fda-on-the-design-of-phase-iii-clinical-trial-for-oraxol-idUSASB0C114", "ord_in_thread": 0, "title": "BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "athenex inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Athenex Inc:\n* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL\n* ATHENEX INC - SECOND INTERIM ANALYSIS OF ORAXOL PHASE III CLINICAL STUDY BASED ON 180 EVALUABLE PATIENTS IS PLANNED FOR MIDDLE OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T21:10:00.000+02:00", "crawled": "2018-01-17T20:06:50.028+02:00", "highlightTitle": ""}